TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer.

Brian Riley as President and Chief Technical Officer, Joanne Lager, MD as Chief Medical Officer, and Adrian Chaisson as Chief of Staff.

In collaboration with GSK, iTeos has decided to discontinue the belrestotug program after it failed to meet key clinical trial endpoints.

WATERTOWN, Mass. and GOSSELIES, Belgium - iTeos Therapeutics, Inc. (NASDAQ: ITOS), a biopharmaceutical company with a market capitalization of $265 million, and its partner GSK have decided to ...

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate ...

WATERTOWN, Mass. and GOSSELIES, Belgium - iTeos Therapeutics, Inc. (NASDAQ: ITOS), a biopharmaceutical company with a market capitalization of $265 million, and its partner GSK have decided to ...

TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...

iTeos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 Phase 2 study on Tuesday. The trial sponsored by GSK Plc (NYSE:GSK ...

WATERTOWN, Mass. and GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...